A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
dose (RD) and to assess the safety and tolerability of ONT-380 combined with ado-trastuzumab
emtansine (T-DM1) in patients with HER2+ breast cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society